Pharmacotherapy for uveitis: current management and emerging therapy

References

• DarrellRWWagenerHPKurlandLTEpidemiology of uveitis. Incidence and prevalence in a small urban communityArch Ophthalmol19626850251413883604
   PubMed Web of Science ®Google Scholar
• Suttorp-SchultenMSRothovaAThe possible impact of uveitis in blindness: a literature surveyBr J Ophthalmol19968098448488962842
   PubMed Web of Science ®Google Scholar
• GoldsteinHThe reported demography and causes of blindness throughout the worldAdv Ophthalmol1980401996153861
   PubMedGoogle Scholar
• ForresterJVUveitis: pathogenesisLancet19913388781149815011683927
   PubMed Web of Science ®Google Scholar
• JabbsDNussenblattRBRosenbaumJTStandardization of Uveitis Nomenclature (SUN) Working GroupStandardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopAm J Ophthalmol200514050951616196117
   PubMed Web of Science ®Google Scholar
• MiserocchiEFogliatoGModoratiGBandelloFReview on the worldwide epidemiology of uveitisEur J Ophthalmol201323570571723661536
   PubMed Web of Science ®Google Scholar
• CiminoLAldigeriRSalvaraniCThe causes of uveitis in a referral centre of Northern ItalyInt Ophthalmol201030552152920229320
   PubMedGoogle Scholar
• CurnowSJScheel-ToellnerDJenkinsonWInhibition of T-cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signalingJ Immunol200417385290529715470075
   PubMed Web of Science ®Google Scholar
• DennistonAKKottoorSHKhanIEndogenous cortisol and TGF-beta in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell functionJ Immunol2011186130531121106846
   PubMed Web of Science ®Google Scholar
• TakeuchiMAlardPStreileinJWTGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cellsJ Immunol19981604158915979469414
   PubMed Web of Science ®Google Scholar
• TakeuchiMKosiewiczMMAlardPStreileinJWOn the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T-cell activationEur J Immunol1997277164816569247573
   PubMed Web of Science ®Google Scholar
• TaylorAWYeeDGNishidaTNambaKNeuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH)Ann N Y Acad Sci200091723924711268350
   PubMed Web of Science ®Google Scholar
• TaylorAWStreileinJWCousinsSWIdentification of alpha- melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humorCurr Eye Res19921112119912061490338
   PubMed Web of Science ®Google Scholar
• GochoKKondoIYamakiKIdentification of Autoreactive T-Cells in Vogt-Koyanagi-Harada DiseaseInvest Ophthalmol Vis Sci20014292004200911481264
   PubMed Web of Science ®Google Scholar
• De SmetMDBitarGMainigiSNussenblattRBHuman S-antigen determinant recognition in uveitisInvest Ophthalmol Vis Sci200142133233323811726628
   PubMed Web of Science ®Google Scholar
• RodriguezACalongeMPedroza-SeresMReferral patterns of uveitis in a tertiary eye care centerArch Ophthalmol199611455935998619771
   PubMed Web of Science ®Google Scholar
• ZaidiAAYingGDanielEHypopyon in patients with uveitisOphthalmology2010117236637220006905
   PubMed Web of Science ®Google Scholar
• BarryRJSutcliffeNIsenbergDaThe Sjögren’s Syndrome Damage Index – a damage index for use in clinical trials and observational studies in primary Sjögren’s syndromeRheumatology20084781193119818524804
   PubMed Web of Science ®Google Scholar
• SkopouliFNDafniUIoannidisJPMoutsopoulosHMClinical evolution, and morbidity and mortality of primary Sjögren’s syndromeSemin Arthritis Rheum200029529630410805354
   PubMed Web of Science ®Google Scholar
• Tempest-RoeSJoshiLDickADTaylorSRLocal therapies for inflammatory eye disease in translation: past, present and futureBMC Ophthalmol20131313923914773
   PubMed Web of Science ®Google Scholar
• DurraniKZakkaFRAhmedMMemonMSiddiqueSSFosterCSSystemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory diseaseSurv Ophthalmol201156647451022117884
   PubMed Web of Science ®Google Scholar
• DennistonAKDickADSystemic therapies for inflammatory eye disease: past, present and futureBMC Ophthalmol2013131823617902
   PubMed Web of Science ®Google Scholar
• Gallego-PinazoRDolz-MarcoRMartínez-CastilloSArévaloJFDíaz-LlopisMUpdate on the principles and novel local and systemic therapies for the treatment of non-infectious uveitisInflamm Allergy Drug Targets2013121384523441991
   PubMedGoogle Scholar
• LarsonTNusseblattRBSenHNEmerging Drugs for UveitisExpert Opin Emerg Drugs201216230932221210752
   PubMed Web of Science ®Google Scholar
• Barisani-AsenbauerTMacaSMMejdoubiLEmmingerWMacholdKAuerHUveitis-a rare disease often associated with systemic diseases and infections-a systematic review of 2,619 patientsOrphanet J Rare Dis201275722932001
   PubMed Web of Science ®Google Scholar
• GritzDCWongIGIncidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis StudyOphthalmology2004111349150015019324
   PubMed Web of Science ®Google Scholar
• SuhlerEBLloydMJChoiDRosenbaumJTAustinDFIncidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific NorthwestAm J Ophthalmol2008146689089619027424
   PubMed Web of Science ®Google Scholar
• HwangDKChouYJPuCYChouPEpidemiology of uveitis among the Chinese population in Taiwan: a population-based studyOphthalmology2012119112371237622809756
   PubMed Web of Science ®Google Scholar
• ReadRWHollandGNRaoNARevised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclatureAm J Ophthalmol2001131564765211336942
   PubMed Web of Science ®Google Scholar
• BodaghiBCassouxNWechslerBChronic severe uveitis: etiology and visual outcome in 927 patients from a single centerMedicine200180426327011470987
   PubMed Web of Science ®Google Scholar
• Bloch-MichelENussenblattRBInternational Uveitis Study Group recommendations for the evaluation of intraocular inflammatory diseaseAm J Ophthalmol198710322342353812627
   PubMed Web of Science ®Google Scholar
• HollandGNStandard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis SocietyAm J Ophthalmol199411756636678172275
   PubMed Web of Science ®Google Scholar
• EngstromREHollandGNMargolisTPThe progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDSOphthalmology19941019148815028090452
   PubMed Web of Science ®Google Scholar
• MandevilleJTLevinsonRDHollandGNThe tubulointerstitial nephritis and uveitis syndromeSurv Ophthalmol200146319520811738428
   PubMed Web of Science ®Google Scholar
• McCannelCAHollandGNHelmCJCornellPJWinstonJVRimmerTGCauses of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study GroupAm J Ophthalmol1996121135468554079
   PubMed Web of Science ®Google Scholar
• HeiligenhausAHeinzCEdelstenCKotaniemiKMindenKReview for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factorsOcul Immunol Inflamm201321318019123713827
   PubMed Web of Science ®Google Scholar
• SmithJAMackensenFSenHNEpidemiology and course of disease in childhood uveitisOphthalmology200911681544155119651312
   PubMed Web of Science ®Google Scholar
• RothovaAvan VeenedaalWGLinssenAGlasiusEKijlstraAde JongPTClinical features of acute anterior uveitisAm J Ophthalmol198710321371453492916
   PubMed Web of Science ®Google Scholar
• LondonNJRathinamSRCunninghamETJrThe epidemiology of uveitis in developing countriesInt Ophthalmol Clin201050211720375859
   PubMedGoogle Scholar
• WakefiledDChangJEpidemiology of uveitisInt Ophthalmol Clin2005452113
   Google Scholar
• BrewertonDACaffreyMNichollsAWaltersDJamesDCAcute anterior uveitis and HL-A 27Lancet197330278369949964127279
   PubMed Web of Science ®Google Scholar
• ChangJHWakefieldDUveitis: a global perspectiveOcul Immunol Inflamm200210426327912854035
   PubMed Web of Science ®Google Scholar
• OhguroNSonodaKHTakeuchiMMatsumuraMMochizukiMThe 2009 prospective multi-center epidemiologic survey of uveitis in JapanJpn J Ophthalmol201256543243522752308
   PubMed Web of Science ®Google Scholar
• ZeinGBertaAFosterCSMultiple sclerosis-associated uveitisOcul Immunol Inflamm200412213714215512983
   PubMed Web of Science ®Google Scholar
• ZierhutMFosterCSMultiple sclerosis, sarcoidosis and other diseases in patients with pars planitisDev Ophthalmol19922341471309708
   PubMedGoogle Scholar
• YangPZhangZZhouHClinical patterns and characteristics of uveitis in a tertiary center for uveitis in ChinaCurr Eye Res2005301194394816282128
   PubMed Web of Science ®Google Scholar
• RathinamSRNamperumalsamyPGlobal variation and pattern changes in epidemiology of uveitisIndian J Ophthalmol200755317318317456933
   PubMedGoogle Scholar
• ChungYMYehTSLiuJHEndogenous uveitis in Chinese – an analysis of 240 cases in a uveitis clinicJpn J Ophthalmol198832164693261815
   PubMed Web of Science ®Google Scholar
• KotakeSFurudateNSasamotoYYoshikawaKGodaCMatsudaHCharacteristics of endogenous uveitis in Hokkaido, JapanGraefes Arch Clin Exp Ophthalmol1996234105996038897050
   PubMed Web of Science ®Google Scholar
• WakabayashiTMorimuraYMiyamotoYOkadaAAChanging patterns of intraocular inflammatory disease in JapanOcul Immunol Inflamm200311427728614704899
   PubMed Web of Science ®Google Scholar
• Tugal-TutkunIBehçet disease in the developing worldInt Ophthalmol Clin2010502879820375864
   PubMedGoogle Scholar
• JabsDABusingyeJApproach to the diagnosis of the uveitidesAm J Ophthalmol2013156222823623668682
   PubMed Web of Science ®Google Scholar
• MandelcornEDInfectious causes of posterior uveitisCan J Ophthalmol2013481313923419296
   PubMed Web of Science ®Google Scholar
• GulyCMForresterJVInvestigation and management of uveitisBMJ2010341c497620943722
   PubMed Web of Science ®Google Scholar
• De Groot-MijnesJDFRothovaAVan LoonAMPolymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitisAm J Ophthalmol2006141231331816458686
   PubMed Web of Science ®Google Scholar
• WongRWJumperJMMcDonaldHREmerging concepts in the management of acute retinal necrosisBr J Ophthalmol201397554555223235944
   PubMed Web of Science ®Google Scholar
• JabsDARosenbaumJTFosterSGuidelines for the Use of Immunosuppressive Drugs in Patients with Ocular Inflammatory Disorders: recommendations of an expert panelAm J Ophthalmol200013049251311024423
   PubMed Web of Science ®Google Scholar
• PatoEMuñoz-FernándezSFranciscoFSystematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitisSemin Arthritis Rheum201140431432320656330
   PubMed Web of Science ®Google Scholar
• Cordero-ComaMYilmazTOnalSSystematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitisOcul Immunol Inflamm2013211192723323577
   PubMed Web of Science ®Google Scholar
• SaadounDBodaghiBBienvenuBBiotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodiesAutoimmun Rev201312777478323470459
   PubMed Web of Science ®Google Scholar
• ChakravartyKMcDonaldHPullarTBSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of DermatologistsRheumatology (Oxford)200847692492516940305
   PubMed Web of Science ®Google Scholar
• Management of DMARDS [webpage on the Internet]National Institute of Health and Clinical Excellence Clinical Knowledge Summaries (UK) [updated January 2013; cited June 19, 2014]. Available from: http://cks.nice.org.uk/dmardsAccessed June 19, 2014
   Google Scholar
• CarryerHMKoelscheGAPrickmanLEMaytumCKLakeCFWilliamsHLEffects of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollenProc Staff Meet Mayo Clin1950251748248615440926
   PubMed Web of Science ®Google Scholar
• GordonDMEffects of pituitary adrenocorticotrophic hormone (ACTH) therapy in ophthalmologic conditionsJ Am Med Assoc1950142161271
   Web of Science ®Google Scholar
• van der VeldenVHGlucocorticoids: mechanisms of action and anti-inflammatory potential in asthmaMediators Inflamm199872292379792333
   PubMed Web of Science ®Google Scholar
• PavesioCEDecoryHHTreatment of ocular inflammatory conditions with loteprednol etabonateBr J Ophthalmol200892445545918245274
   PubMed Web of Science ®Google Scholar
• BeckerBMillsDWElevated intraocular pressure following corticosteroid eye dropsJ Am Med Assoc1963185884886
   PubMed Web of Science ®Google Scholar
• NguyenQDHatefEKayenBA cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United StatesOphthalmology2011118118419020678806
   PubMed Web of Science ®Google Scholar
• RühlmannANordheimAEffects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulationImmunobiology19971981–31922069442391
   PubMed Web of Science ®Google Scholar
• HoSClipstoneNTimmermannLThe mechanism of action of cyclosporin A and FK506Clin Immunol Immunopathol1996803 Pt 2S40S458811062
   PubMedGoogle Scholar
• KaçmazROKempenJHNewcombCCyclosporine for Ocular Inflammatory DiseasesOphthalmology2011117357658420031223
   PubMed Web of Science ®Google Scholar
• MasudaKNakajimaAUrayamaANakaeKKogureMInabaGDouble-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s diseaseLancet198918647109310962566048
   PubMed Web of Science ®Google Scholar
• NussenblattRBPalestineAGRookAHScherIWackerWBGeryITreatment of intraocular inflammatory disease with cyclosporin ALancet1983283442352386135075
   PubMed Web of Science ®Google Scholar
• GrahamEMSandersMDJamesDGHamblinAKasp GrochowskaEDumondeDCyclosporin A in the treatment of posterior uveitisTrans Ophthalmol Soc U K198510421461513857775
   PubMedGoogle Scholar
• MurphyCCGreinerKPlskovaJCyclosporine vs tacrolimus therapy for posterior and intermediate uveitisArch Ophthalmol2005123563464115883282
   PubMedGoogle Scholar
• ChanGLCanafaxDMJohnsonCAThe therapeutic use of azathioprine in renal transplantationPharmacotherapy1987751651773324057
   PubMed Web of Science ®Google Scholar
• OkadaAAImmunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literatureOcul Immunol Inflamm200513533535116419419
   PubMed Web of Science ®Google Scholar
• Hoang-XaunTFosterCSRiceBAScleritis in relapsing polychondritis. Response to therapyOphthalmology19909778928982381703
   PubMed Web of Science ®Google Scholar
• SawVPDartJKRauzSImmunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomesOphthalmology2008115225326117655931
   PubMed Web of Science ®Google Scholar
• HemadyRKBaerJCFosterCSImmunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritisInt Ophthalmol Clin19923212412521537661
   PubMedGoogle Scholar
• NewellFWKrillAETreatment of uveitis with azathioprine (Imuran)Trans Ophthalmol Soc U K1967874995115255241
   PubMedGoogle Scholar
• MooreCESympathetic ophthalmitis treated with azathioprineBr J Ophthalmol19685296886905725168
   PubMed Web of Science ®Google Scholar
• YaziciHPazarliHBarnesCA controlled trial of azathioprine in Behcet’s syndromeN Engl J Med199032252812852404204
   PubMed Web of Science ®Google Scholar
• PasadhikaSKempenJHNewcombCAzathioprine for Ocular Inflammatory DiseaseAm J Ophthalmol2009148450050919570522
   PubMed Web of Science ®Google Scholar
• CadeRMarsDPrivetteMEffect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroidsArch Intern Med198614647377413963956
   PubMedGoogle Scholar
• SinghGFriesJFSpitzPWilliamsCAToxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspectiveArthritis Rheum19893278378432751718
   PubMed Web of Science ®Google Scholar
• AstenPBarrettJSymmonsDRisk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseasesJ Rheumatol19992681705171410451066
   PubMed Web of Science ®Google Scholar
• PennIMalignancies associated with immunosuppressive or cytotoxic therapySurgery1978835492502347611
   PubMed Web of Science ®Google Scholar
• KempenJHGangaputraSDanielELong term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidenceAm J Ophthalmol2009146680281218579112
   PubMed Web of Science ®Google Scholar
• SamsonCMWaheedNBaltatzisSFosterCSMethotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patientsOphthalmology200110861134113911382642
   PubMed Web of Science ®Google Scholar
• BomSZamiriPLightmanSUse of methotrexate in the management of sight-threatening uveitisOcul Immunol Inflamm200191354011262666
   PubMed Web of Science ®Google Scholar
• HolzFGKrastelHBreitbartASchwarz-EywillMPezzuttoAVölckerHELow-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroidsGer J Ophthalmol199213–41421441483126
   PubMedGoogle Scholar
• Kaplan-MessasABarkanaYAvniINeumannRMethotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritisOcul Immunol Inflamm200311213113914533032
   PubMed Web of Science ®Google Scholar
• ShahSSLowderCYSchmittMAWilkeWSKosmorskyGSMeislerDMLow-dose methotrexate therapy for ocular inflammatory diseaseOphthalmology1992999141914231407973
   PubMed Web of Science ®Google Scholar
• GangaputraSNewcombCWLiesegangTLMethotrexate for Ocular Inflammatory DiseasesOphthalmology2009116112188219819748676
   PubMed Web of Science ®Google Scholar
• KremerJMAlarcónGSLightfootRWJrMethotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of RheumatologyArthritis Rheum19943733163288129787
   PubMed Web of Science ®Google Scholar
• AllisonACEuguiEMImmunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetilImmunol Rev19931365287907572
   PubMed Web of Science ®Google Scholar
• BaltatzisSTufailFYuENVredeveldCMFosterCSMycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disordersOphthalmology200311051061106512750115
   PubMed Web of Science ®Google Scholar
• SobrinLChristenWFosterCSMycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitisOphthalmology200811581416142118221998
   PubMed Web of Science ®Google Scholar
• DanielEThorneJENewcombCWMycophenolate mofetil for ocular inflammationAm J Ophthalmol2010149342343220042178
   PubMed Web of Science ®Google Scholar
• AhmedARHombalSMCyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical usesJ Am Acad Dermatol1984116111511266392368
   PubMed Web of Science ®Google Scholar
• De GrootKHarperLJayneDRWPulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trialAnn Intern Med20091501067068019451574
   PubMed Web of Science ®Google Scholar
• AduDPallALuqmaniRAControlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitisQJM19979064014099205678
   PubMed Web of Science ®Google Scholar
• DurraniKPapaliodisGNFosterCSPulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safetyOphthalmology2004111596096515121375
   PubMed Web of Science ®Google Scholar
• CarruthersDMRational therapy in systemic necrotising vasculitisClin Med200117911358081
   PubMed Web of Science ®Google Scholar
• KhanIJBarryRJAmissah-ArthurKNTen-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory diseaseBr J Ophthalmol20129791118112223203696
   PubMed Web of Science ®Google Scholar
• PujariSSKempenJHNewcombCWCyclophosphamide for ocular inflammatory diseasesOphthalmology2011117235636519969366
   PubMed Web of Science ®Google Scholar
• Martin-SuarezID’CruzDMansoorMFernandesAPKhamashtaMAHughesGRImmunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamideAnn Rheum Dis1997564814879306871
   PubMed Web of Science ®Google Scholar
• KempenJHDanielEDunnJPOverall and cancer related mortality among patients withBMJ2009339b248019578087
   PubMedGoogle Scholar
• BlumenfeldZHaimNPrevention of gonadal damage during cytotoxic therapyAnn Med19972931992069240625
   PubMed Web of Science ®Google Scholar
• NewellDRCalvertAHHarrapKRMcElwainTJStudies on the pharmacokinetics of chlorambucil and prednimustine in manBr J Clin Pharmacol19831522532586849759
   PubMed Web of Science ®Google Scholar
• MudunBAErgenAIpciogluSUBurumcekEYDurluYArslanMOShort-term chlorambucil for refractory uveitis in Behcet’s diseaseOcul Immunol Inflamm20019421922911935432
   PubMed Web of Science ®Google Scholar
• GoldsteinDAFontanillaFAKaulSSahinOTesslerHHLong-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammationOphthalmology2002109237037711825825
   PubMed Web of Science ®Google Scholar
• MiserocchiEBaltatzisSEkongARoqueMFosterCSEfficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experienceOphthalmology2002109113714211772593
   PubMed Web of Science ®Google Scholar
• WooleyPHDutcherJWidmerMBGillisSInfluence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in miceJ Immunol199315111660266078245488
   PubMed Web of Science ®Google Scholar
• ScallonBCaiASolowskiNBinding and functional comparisons of two types of tumor necrosis factor antagonistsJ Pharmacol Exp Ther2002301241842611961039
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHKnightDMGhrayebJChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine1995732512597640345
   PubMed Web of Science ®Google Scholar
• LinJZiringDDesaiSTNFa blockade in human diseases: an overview of efficacy and safetyClin Immunol20091261133017916445
   PubMed Web of Science ®Google Scholar
• BraunJBrandtJListingJLong-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trialArthritis Rheum20034882224223312905476
   PubMed Web of Science ®Google Scholar
• SobrinLKimECChristenWPapadakiTLetkoEFosterCSInfliximab therapy for the treatment of refractory ocular inflammatory diseaseArch Ophthalmol2007125789590017620567
   PubMed Web of Science ®Google Scholar
• LeeFFFosterCSPharmacotherapy of uveitisExpert Opin Pharmacother20101171135114620367272
   PubMed Web of Science ®Google Scholar
• NiccoliLNanniniCBenucciMLong-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up studyRheumatology (Oxford)20074671161116417478466
   PubMed Web of Science ®Google Scholar
• MarkomichelakisNDelichaEMasselosSFragiadakiKKaklamanisPSfikakisPPA single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week studyRheumatology (Oxford)201150359359721097877
   PubMed Web of Science ®Google Scholar
• SfikakisPPKaklamanisPHElezoglouAInfliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet diseaseAnn Intern Med2004140540440614996689
   PubMed Web of Science ®Google Scholar
• ArtornsombudhPGevorgyanOPayalASiddiqueSSFosterCSInfliximab treatment of patients with birdshot retinochoroidopathyOphthalmology2013120358859223177362
   PubMed Web of Science ®Google Scholar
• KahnPWeissMImundoLFLevyDMFavorable response to high-dose infliximab for refractory childhood uveitisOphthalmology2006113586086416545455
   PubMed Web of Science ®Google Scholar
• RajaramanRTKimuraYLiSHainesKChuDSRetrospective case review of pediatric patients with uveitis treated with infliximabOphthalmology2006113230831416406545
   PubMed Web of Science ®Google Scholar
• BaughmanRPBradleyDALowerEEInfliximab in chronic ocular inflammationInt J Clin Pharmacol Ther200543171115704608
   PubMed Web of Science ®Google Scholar
• BodaghiBBui QuocEWechslerBTherapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factorsAnn Rheum Dis200564696296415897316
   PubMed Web of Science ®Google Scholar
• SuhlerEBSmithJRWertheimMSA prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomesArch Ophthalmol2005123790391216009830
   PubMedGoogle Scholar
• SuhlerEBSmithJRGilesTRInfliximab therapy for refractory uveitis: 2-year results of a prospective trialArch Ophthalmol2009127681982219506209
   PubMed Web of Science ®Google Scholar
• KaymakcalanZSakorafasPBoseSComparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factorClin Immunol2009131230831619188093
   PubMed Web of Science ®Google Scholar
• RudwaleitMRødevandEHolckPAdalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label studyAnn Rheum Dis200968569670118662932
   PubMed Web of Science ®Google Scholar
• DobnerBCMaxRBeckerMDA three-centre experience with adalimumab for the treatment of non-infectious uveitisBr J Ophthalmol201397213413823212204
   PubMed Web of Science ®Google Scholar
• SenESSharmaSHinchcliffeADickADRamananAVUse of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease – a case cohort interventional studyRheumatology (Oxford)201251122199220322923752
   PubMed Web of Science ®Google Scholar
• Diaz-LlopisMGarcía-DelpechSSalomDAdalimumab therapy for refractory uveitis: a pilot studyJ Ocul Pharmacol Ther200824335136118476805
   PubMed Web of Science ®Google Scholar
• TynjäläPKotaniemiKLindahlPAdalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitisRheumatology (Oxford)200847333934418238789
   PubMed Web of Science ®Google Scholar
• CalabreseLHMolecular differences in anticytokine therapiesClin Exp Rheumatol200321224124812747285
   PubMed Web of Science ®Google Scholar
• ReiffATakeiSSadeghiSEtanercept therapy in children with treatment-resistant uveitisArthritis Rheum20014461411141511407702
   PubMed Web of Science ®Google Scholar
• ReiffALong-term outcome of etanercept therapy in children with treatment-refractory uveitisArthritis Rheum20034872079208012847709
   PubMed Web of Science ®Google Scholar
• SmithJRLevinsonRDHollandGNDifferential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic diseaseArthritis Rheum200145325225711409666
   PubMed Web of Science ®Google Scholar
• QuartierPTaupinPBourdeautFEfficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis Rheum20034841093110112687553
   PubMed Web of Science ®Google Scholar
• SmithJAThompsonDJWhitcupSMA randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritisArthritis Rheum2005531182315696578
   PubMed Web of Science ®Google Scholar
• FosterCSTufailFWaheedNKEfficacy of etanercept in preventing relapse of uveitis controlled by methotrexateArch Ophthalmol2003121443744012695239
   PubMed Web of Science ®Google Scholar
• GalorAPerezVLHammelJPLowderCYDifferential effectiveness of etanercept and infliximab in the treatment of ocular inflammationOphthalmology2006113122317232316996615
   PubMed Web of Science ®Google Scholar
• TreonSPAndersonKCThe use of rituximab in the treatment of malignant and nonmalignant plasma cell disordersSemin Oncol2000276 Suppl 12798511226004
   PubMed Web of Science ®Google Scholar
• LimLSuhlerEBSmithJRBiologic therapies for inflammatory eye diseaseClin Experiment Ophthalmol200634436537416764659
   PubMed Web of Science ®Google Scholar
• HeiligenhausAMiserocchiEHeinzCGerloniVKotaniemiKTreatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)Rheumatology (Oxford)20115081390139421378109
   PubMed Web of Science ®Google Scholar
• SadreddiniSNoshadHMolaeefardMNoshadRTreatment of retinal vasculitis in Behçet’s disease with rituximabMod Rheumatol200818330630818438602
   PubMed Web of Science ®Google Scholar
• DavatchiFShamsHRezaipoorMRituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study)Int J Rheum Dis201013324625220704622
   PubMed Web of Science ®Google Scholar
• MiserocchiEPontikakiIModoratiGBandelloFMeroniPLGerloniVRituximab for uveitisOphthalmology2011118122322421199719
   PubMed Web of Science ®Google Scholar
• Tomkins-NetzerOTaylorSRLightmanSCan rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?Ophthalmologica2013230310911523948944
   PubMed Web of Science ®Google Scholar
• Rubbert-RothATakPPZerbiniCEfficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)Rheumatology (Oxford)20104991683169320463186
   PubMed Web of Science ®Google Scholar
• KeatingGMAbatacept: a review of its use in the management of rheumatoid arthritisDrugs201373101095111923794171
   PubMed Web of Science ®Google Scholar
• PasadhikaSRosenbaumJTUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitisBiologics20148678124600203
   PubMedGoogle Scholar
• Angeles-HanSFlynnTLehmanTAbatacept for refractory juvenile idiopathic arthritis-associated uveitis-a case reportJ Rheumatol20083591897189818785302
   PubMed Web of Science ®Google Scholar
• ZulianFBalzarinMFalciniFAbatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitisArthritis Care Res (Hoboken)201062682182520191477
   PubMed Web of Science ®Google Scholar
• KenawyNClearyGMewarDBeareNChandnaAPearceIAbatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitisGraefes Arch Clin Exp Ophthalmol2011249229730020922440
   PubMed Web of Science ®Google Scholar
• YangHWangJDuJStructural basis of immunosuppression by the therapeutic antibody daclizumabCell Res201020121361137120820193
   PubMed Web of Science ®Google Scholar
• BhatPCastañeda-CervantesRADoctorPPFosterCSIntravenous daclizumab for recalcitrant ocular inflammatory diseaseGraefes Arch Clin Exp Ophthalmol2009247568769219198869
   PubMed Web of Science ®Google Scholar
• PapaliodisGNChuDFosterCSTreatment of ocular inflammatory disorders with daclizumabOphthalmology2003110478678912689903
   PubMed Web of Science ®Google Scholar
• SenHNLevy-ClarkeGFaiaLJHigh-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitisAm J Ophthalmol2009148569670319664754
   PubMed Web of Science ®Google Scholar
• WebsterACRusterLPMcGeeRInterleukin 2 receptor antagonists for kidney transplant recipientsCochrane database Syst Rev20101CD00389720091551
   PubMed Web of Science ®Google Scholar
• NussenblattRBFortinESchiffmanRTreatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trialProc Natl Acad Sci U S A199996137462746610377437
   PubMed Web of Science ®Google Scholar
• NussenblattRBThompsonDJLiZHumanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJ Autoimmun200321328329314599854
   PubMed Web of Science ®Google Scholar
• SobrinLHuangJJChristenWKafkalaCChoopongPFosterCSDaclizumab for treatment of birdshot chorioretinopathyArch Ophthalmol2008126218619118268208
   PubMed Web of Science ®Google Scholar
• YehSWroblewskiKBuggageRHigh-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, noninfectious uveitisJ Autoimmmun20093129197
   Web of Science ®Google Scholar
• BuggageRRLevy-ClarkeGSenHNA double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s diseaseOcul Immunol Inflamm2007152637017558830
   PubMed Web of Science ®Google Scholar
• DeuterCStübigerNZierhutMInterferon-α therapy in noninfectious uveitisDev Ophthalmol201251909722517207
   PubMedGoogle Scholar
• GueudryJWechslerBTerradaCLong-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet diseaseAm J Ophthalmol2008146683784419027420
   PubMed Web of Science ®Google Scholar
• KötterIGünaydinIZierhutMStübigerNThe use of interferon alpha in Behçet disease: review of the literatureSemin Arthritis Rheum200433532033515079763
   PubMed Web of Science ®Google Scholar
• BeckerMDHeiligenhausAHuddeTInterferon as a treatment for uveitis associated with multiple sclerosisBr J Ophthalmol200589101254125716170111
   PubMed Web of Science ®Google Scholar
• MackensenFMaxRBeckerMDInterferons and their potential in the treatment of ocular inflammationClin Ophthalmol2009355956619898628
   PubMedGoogle Scholar
• SteinMRThe new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulinsPostgrad Med2010122517618420861601
   PubMed Web of Science ®Google Scholar
• KazatchkineMDKaveriSVImmunomodulation of autoimmune and inflammatory diseases with intravenous immune globulinN Engl J Med20013451074775511547745
   PubMed Web of Science ®Google Scholar
• OnalSFosterCSAhmedAREfficacy of intravenous immunoglobulin treatment in refractory uveitisOcul Immunol Inflamm200614636737417162608
   PubMed Web of Science ®Google Scholar
• LeHoangPCassouxNGeorgeFKullmannNKazatchkineMDIntravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathyOcul Immunol Inflamm200081495710806434
   PubMed Web of Science ®Google Scholar
• SeiderNBeiranIScharfJMillerBIntravenous immunoglobulin therapy for resistant ocular Behçet’s diseaseBr J Ophthalmol200185111287128811673289
   PubMed Web of Science ®Google Scholar
• González-DelgadoMGonzálezCBlázquezJISalas-PuigJCastroJHernández-LahozCIntravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndromeNeurologia2004197401403 Spanish15273890
   PubMed Web of Science ®Google Scholar
• WeissKSteinbruggerIWegerMIntravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumabEye (Lond)20092391812181819169227
   PubMed Web of Science ®Google Scholar
• FineHFBaffiJReedGFCsakyKGNussenblattRBAqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edemaAm J Ophthalmol2001132579479611704050
   PubMed Web of Science ®Google Scholar
• Cordero ComaMSobrinLOnalSChristenWFosterCSIntravitreal bevacizumab for treatment of uveitic macular edemaOphthalmology200711481574157917363060
   PubMed Web of Science ®Google Scholar
• MackensenFHeinzCBeckerMDHeiligenhausAIntravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyRetina2008281414518185136
   PubMed Web of Science ®Google Scholar
• AcharyaNRHongKCLeeSMRanibizumab for refractory uveitis-related macular edemaAm J Ophthalmol2009148230330919427988
   PubMed Web of Science ®Google Scholar
• LasaveAFZeballosDGEl-HaigWMDíaz-LlopisMSalomDArevaloJFShort-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edemaOcul Immunol Inflamm200917642343020001264
   PubMed Web of Science ®Google Scholar
• BaeJHLeeCSLeeSCEfficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edemaRetina201131111111820856170
   PubMed Web of Science ®Google Scholar
• SoheilianMRabbanikhahZRamezaniAKiavashVYaseriMPeymanGAIntravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot studyJ Ocul Pharmacol Ther201026219920620307215
   PubMed Web of Science ®Google Scholar
• Cervantes-CastañedaRAGiuliariGPGallagherMJIntravitreal bevacizumab in refractory uveitic macular edema: one-year follow-upEur J Ophthalmol200919462262919551679
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• InoueMTakedaKMoritaKYamadaMTanigawaraYOguchiYVitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injectionAm J Ophthalmol200413861046104815629301
   PubMed Web of Science ®Google Scholar
• Van KooijBRothovaAde VriesPThe pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edemaOcul Immunol Inflamm2006142738516597536
   PubMed Web of Science ®Google Scholar
• Chang-LinJEAttarMAcheampongAAPharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implantInvest Ophthalmol Vis Sci2011521808620702826
   PubMed Web of Science ®Google Scholar
• Da SilvaGRda Silva CunhaAJrAyresEOréficeRLEffect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugsJ Mater Sci Mater Med200920248148718853235
   PubMed Web of Science ®Google Scholar
• LowderCBelfortRLightmanSDexamethasone intravitreal implant for noninfectious intermediate or posterior uveitisArch Ophthalmol2011129554555321220619
   PubMed Web of Science ®Google Scholar
• AdánAPelegrínLReyADexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patientsRetina20133371435144023514796
   PubMed Web of Science ®Google Scholar
• TaylorSRJTomkins-NetzerOJoshiLMorarjiJMcLooneELightmanSDexamethasone implant in pediatric uveitisOphthalmology2012119112412241223122465
   PubMed Web of Science ®Google Scholar
• JaffeGJBen-NunJGuoHDunnJPAshtonPFluocinolone acetonide sustained drug delivery device to treat severe uveitisOphthalmology2000107112024203311054326
   PubMed Web of Science ®Google Scholar
• HunterRSLoboAMDexamethasone intravitreal implant for the treatment of noninfectious uveitisClin Ophthalmol201151613162122140307
   PubMedGoogle Scholar
• JaffeGJMartinDCallananDPearsonPALevyBComstockTFluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical studyOphthalmology200611361020102716690128
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment (MUST) Trial Research GroupKempenJHAltaweelMMRandomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trialOphthalmology2011118101916192621840602
   PubMed Web of Science ®Google Scholar
• CallananDGJaffeGJMartinDFPearsonPAComstockTLTreatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial resultsArch Ophthalmol200812691191120118779477
   PubMedGoogle Scholar
• KaneFEBurdanJCutinoAGreenKEIluvien: a new sustained delivery technology for posterior eye diseaseExpert Opin Drug Deliv2008591039104618754752
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHafizGShahSMSustained ocular delivery of fluocinolone acetonide by an intravitreal insertOphthalmology201011771393139920202684
   PubMed Web of Science ®Google Scholar
• SanfordMFluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedemaDrugs201373218719323335133
   PubMed Web of Science ®Google Scholar
• Focused Therapeutics/Visionary Science [webpage on the Internet]WatertownpSivida Corp [cited April 15, 2014]. Available from: http://www.psivida.com/Accessed June 19, 2014
   Google Scholar
• ChenJNovel regulatory mechanisms of mTOR signalingCurr Top Microbiol Immunol200427924525714560961
   PubMed Web of Science ®Google Scholar
• KangJHuddlestonSJFraserJMKhorutsADe novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T-cells in vivo following systemic antigen administration accompanied by blockade of mTORJ Leukoc Biol20088351230123918270248
   PubMed Web of Science ®Google Scholar
• ZeiserRLeveson-GowerDBZambrickiEADifferential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T-cells compared with conventional CD4+ T-cellsBlood2008111145346217967941
   PubMed Web of Science ®Google Scholar
• BruynGATateGCaeiroFEverolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept studyAnn Rheum Dis20086781090109518037627
   PubMed Web of Science ®Google Scholar
• LieberthalWFuhroRAndryCCRapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cellsAm J Physiol Renal Physiol20012814F693F70611553517
   PubMed Web of Science ®Google Scholar
• TenderichGFuchsUZittermannAMuckelbauerRBertholdHKKoerferRComparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipientsClin Transplant200721453654317645716
   PubMed Web of Science ®Google Scholar
• CroweABruelisauerADuerrLGuntzPLemaireMAbsorption and intestinal metabolism of SDZ-RAD and rapamycin in ratsDrug Metab Dispos199927562763210220493
   PubMed Web of Science ®Google Scholar
• HeiligenhausAZurek-ImhoffBRoeselMHennigMRammrathDHeinzCEverolimus for the treatment of uveitis refractory to cyclosporine A: a pilot studyGraefes Arch Clin Exp Ophthalmol2013251114315223073842
   PubMed Web of Science ®Google Scholar
• SehgalSSirolimus: its discovery, biological properties, and mechanism of actionTransplant Proc2003353S7S14
   PubMed Web of Science ®Google Scholar
• VerouxMTallaritaTCoronaDD’AssoroAGurrieriCVerouxPSirolimus in solid organ transplantation: current therapies and new frontiersImmunotherapy20113121487149722091684
   PubMed Web of Science ®Google Scholar
• DasariTWPatelBSaucedoJFSystematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of in-stent restenosisAm J Cardiol201311291322132723932188
   PubMed Web of Science ®Google Scholar
• JavaidMMChowdhurySHendersonAOlsburghJAdvanced native kidney renal cell carcinoma in renal transplant recipients: role of sirolimus as dual anti-cancer and anti-rejection agentClin Nephrol201379215416023364206
   PubMed Web of Science ®Google Scholar
• ShanmuganathanVACaselyEMRajDThe efficacy of sirolimus in the treatment of patients with refractory uveitisBr J Ophthalmol200589666666915923497
   PubMed Web of Science ®Google Scholar
• PhillipsBNWroblewskiKJA retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitisJ Ophthalmic Inflamm Infect201111293421475659
   PubMedGoogle Scholar
• SenHNLarsonTAMelethADSmithWMNussenblattRBSunconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trialAm J Ophthalmol201215361038104222465364
   PubMed Web of Science ®Google Scholar
• NguyenQDIbrahimMAWattersAOcular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyJ Ophthalmic Inflamm Infect2013313223514595
   PubMedGoogle Scholar
• Santen IncStudy Assessing Double-masked Uveitis Treatment (SAKURA) Available from: http://clinicaltrials.gov/show/NCT01358266. NLM identifier: NCT01358266Accessed June 19, 2014
   Google Scholar
• DumontFJISAtx-247 (Isotechnika/Roche)Curr Opin Investig Drugs200455542550
   PubMedGoogle Scholar
• AspesletLFreitagDTrepanierDISA(TX)247: a novel calcineurin inhibitorTransplant Proc2001331048105111267185
   PubMed Web of Science ®Google Scholar
• BissonnetteRPappKPoulinYA randomized, multi-center, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasisJ Acad Dermatology2006543472478
   PubMed Web of Science ®Google Scholar
• PappKBissonnetteRRosophLEfficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III studyLancet20083711337134218424323
   PubMed Web of Science ®Google Scholar
• AngladeEAspesletLJWeissSLA new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporinClin Ophthalmol20082469370219668418
   PubMedGoogle Scholar
• RoeselMTappeinerCHeiligenhausAHeinzCOral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitisClin Ophthalmol201151309131321966207
   PubMedGoogle Scholar
• SchultzCVoclosporin as a treatment for noninfectious uveitisOphthalmol Eye Dis2013551023700374
   PubMedGoogle Scholar
• Voclosporin uveitis study fails to meet primary endpoint [webpage on the Internet]Santa MonicaAdvanstar Communications, Inc2013 [updated Jan 2, 2013; cited March 20, 2014]. Available from: http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/modernmedicine/modern-medicine-feature-articles/voclosporin-uveitis-study-faAccessed June 19, 2014
   Google Scholar
• MesquidaMVictoria HernándezMLlorençVBehçet disease-associated uveitis successfully treated with golimumabOcul Immunol Inflamm201321216016223252659
   PubMed Web of Science ®Google Scholar
• WilliamMFaezSPapaliodisGNLoboAGolimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitisJ Ophthalmic Inflamm Infect2012223123322581347
   PubMedGoogle Scholar
• MiserocchiEModoratiGPontikakiIMeroniPLGerloniVLong-term treatment with golimumab for severe uveitisOcul Immunol Inflamm2014222909524143896
   PubMed Web of Science ®Google Scholar
• Cordero-ComaMSalomDDíaz-LlopisMLópez-PratsMJCallejaSGolimumab for uveitisOphthalmology201111891892.e3e421889663
   PubMed Web of Science ®Google Scholar
• FaezSLoboAMSobrinLPapaliodisGNTreatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case seriesClin Experiment Ophthalmol201442439239524024585
   PubMed Web of Science ®Google Scholar
• Sánchez-CanoDCallejas-RubioJLRuiz-VillaverdeRRíos- FernándezROrtego-CentenoNOff-label uses of anti-TNF therapy in three frequent disorders: Behçet’s disease, sarcoidosis, and noninfectious uveitisMediators Inflamm2013201328685723983404
   PubMed Web of Science ®Google Scholar
• TlucekPSStoneDUCertolizumab pegol therapy for rheumatoid arthritis-associated scleritisCornea2012311909121941174
   PubMed Web of Science ®Google Scholar
• DinarelloCASimonAvan der MeerJWTreating Inflammation by blocking interleukin-1 in a broad spectrum of diseasesNat Rev Drug Discov201211863365222850787
   PubMed Web of Science ®Google Scholar
• TeohSCSharmaSHoganALeeRRamananAVDickADTailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndromeBr J Ophthalmol200791226326417244662
   PubMed Web of Science ®Google Scholar
• MesquidaMMolinsBLlorençVCurrent and future treatments for Behçet’s uveitis: road to remissionInt Ophthalmol201434236538123729309
   PubMed Web of Science ®Google Scholar
• IssafrasHCorbinJAGoldfineIDRoellMKDetailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating propertiesJ Pharmacol Exp Ther2014348120221524194526
   PubMed Web of Science ®Google Scholar
• GülATugal-TutkunIDinarelloCAInterleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot studyAnn Rheum Dis201271456356622084392
   PubMed Web of Science ®Google Scholar
• EyeGuard Study [homepage on the Internet]Eyeguard2013 [cited March 20, 2014]. Available from: http://www.eyeguard.comAccessed June 19, 2014
   Google Scholar
• LachmannHJKone-PautIKuemmerle-DeschnerJBUse of canakinumab in the cryopyrin-associated periodic syndromeN Engl J Med20093602416242519494217
   PubMed Web of Science ®Google Scholar
• UgurluSUcarDSeyahiEHatemiGYurdakulSCanakinumab in a patient with juvenile Behcet’s syndrome with refractory eye diseaseAnn Rheum Dis20127191589159122586166
   PubMed Web of Science ®Google Scholar
• SimoniniGXuZCaputoRClinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitisArthritis Rheum201365251351823124805
   PubMed Web of Science ®Google Scholar
• IsaacsJDWattsRAHazlemanBLHumanised monoclonal antibody therapy for rheumatoid arthritisLancet199234088227487521356177
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• IsaacsJHaleGWaldmannHMonoclonal antibody therapy of chronic intraocular inflammation using Campath-1HBr J Ophthalmol19957911105410558534657
   PubMed Web of Science ®Google Scholar
• DickADMeyerPJamesTCampath-1H therapy in refractory ocular inflammatory diseaseBr J Ophthalmol200084110710910611109
   PubMed Web of Science ®Google Scholar
• WangJIbrahimMTurkcuogluPIntercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edemaOcul Immunol Inflamm201018539539820666682
   PubMed Web of Science ®Google Scholar
• FaiaLJSenHNLiZYehSWroblewskiKJNussenblattRBTreatment of inflammatory macular edema with humanized anti-CD11a antibody therapyInvest Ophthalmol Vis Sci20115296919692421498606
   PubMed Web of Science ®Google Scholar
• TalamontiMTeoliMBottiESpalloneGChimentiSCostanzoAPatients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspensionDermatology2011222325025521494026
   PubMed Web of Science ®Google Scholar
• VenkiteshwaranATocilizumabMAbs20091543243820065633
   PubMed Web of Science ®Google Scholar
• RomanoMSironiMToniattiCRole of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitmentImmunity1997633153259075932
   PubMed Web of Science ®Google Scholar
• SimonDDennistonAKTomlinsPJSoluble gp130, an antagonist of IL-6 transsignaling, is elevated in uveitis aqueous humorInvest Ophthalmol Vis Sci20084993988399118469182
   PubMed Web of Science ®Google Scholar
• MesquidaMLeszczynskaALlorençVAdánAInterleukin-6 blockade in ocular inflammatory diseasesClin Exp Immunol2014176330130924528300
   PubMed Web of Science ®Google Scholar
• TappeinerCHeinzCGanserGHeiligenhausAIs tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?J Rheumatol20123961294129522661419
   PubMed Web of Science ®Google Scholar
• HiranoTOhguroNHohkiSA case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumabMod Rheumatol201222229830221748365
   PubMed Web of Science ®Google Scholar
• OshitariTKajitaFTobeARefractory uveitis in patient with castleman disease successfully treated with tocilizumabCase Rep Ophthalmol Med2012201296818023198204
   PubMedGoogle Scholar
• AdánAMesquidaMLlorençVTocilizumab treatment for refractory uveitis-related cystoid macular edemaGraefes Arch Clin Exp Ophthalmol2013251112627263223893042
   PubMed Web of Science ®Google Scholar
• TsangACRothJGottliebCTocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patientOcul Immunol Inflamm201422215515724377416
   PubMed Web of Science ®Google Scholar
• AdánALlorençVMesquidaMPelegrínLTocilizumab treatment for recalcitrant uveitic macular edemaGraefes Arch Clin Exp Ophthalmol201325192249225023271335
   PubMed Web of Science ®Google Scholar
• MuselierABielefeldPBidotSVinitJBesancenotJFBronAEfficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitisOcul Immunol Inflamm201119538238321970668
   PubMed Web of Science ®Google Scholar
• WendlingDDernisEPratiCFrischEDelboscBOnset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect?J Rheumatol20113810228421965707
   PubMed Web of Science ®Google Scholar
• SatoTMinakuchiSMochizukiMTakeuchiMAcute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritisClin Ophthalmol2014818719024531503
   PubMedGoogle Scholar
• SanofiPhase II Study to Analyze Sarilumab in Non-Infectious Uveitis (SARILNIUSATURN) Available from: http://clinicaltrials.gov/ct2/show/NCT01900431. NLM identifier: NCT01900431Accessed June 19, 2014
   Google Scholar
• KollsJKLindénAInterleukin-17 family members and inflammationImmunity200421446747615485625
   PubMed Web of Science ®Google Scholar
• XuSCaoXInterleukin-17 and its expanding biological functionsCell Mol Immunol20107316417420383173
   PubMed Web of Science ®Google Scholar
• FujinoSAndohABambaSIncreased expression of interleukin 17 in inflammatory bowel diseaseGut2003521657012477762
   PubMed Web of Science ®Google Scholar
• TzartosJSFrieseMACranerMJInterleukin-17 production in central nervous system-infiltrating T-cells and glial cells is associated with active disease in multiple sclerosisAm J Pathol2008172114615518156204
   PubMed Web of Science ®Google Scholar
• LubbertsEKoendersMIvan den BergWBThe role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal modelsArthritis Res Ther200571293715642151
   PubMed Web of Science ®Google Scholar
• PatelDDLeeDMKolbingerFAntoniCEffect of IL-17A blockade with secukinumab in autoimmune diseasesAnn Rheum Dis201372Suppl 2ii116ii12323253932
   PubMed Web of Science ®Google Scholar
• ZhouRHoraiRMattapallilMJCaspiRRA new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acidJ Immunol201118784170417721918194
   PubMed Web of Science ®Google Scholar
• ZhouRHoraiRSilverPBThe living eye “disarms” uncommitted autoreactive T-cells by converting them to Foxp3(+) regulatory cells following local antigen recognitionJ Immunol201218841742175022238462
   PubMed Web of Science ®Google Scholar
• HamzaouiKHamzaouiAGuemiraFBessioudMHamzaMAyedKCytokine profile in Behçet’s disease patients. Relationship with disease activityScand J Rheumatol200231420521012369651
   PubMed Web of Science ®Google Scholar
• ChiWZhuXYangPUpregulated IL-23 and IL-17 in Behçet patients with active uveitisInvest Ophthalmol Vis Sci20084973058306418579762
   PubMed Web of Science ®Google Scholar
• Amadi-ObiAYuCRLiuXTH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1Nat Med200713671171817496900
   PubMed Web of Science ®Google Scholar
• DickADTugal-TutkunIFosterSSecukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trialsOphthalmology2013120477778723290985
   PubMed Web of Science ®Google Scholar
• DavidOJKovarikJMSchmouderRLClinical pharmacokinetics of fingolimodClin Pharmacokinet2012511152822149256
   PubMed Web of Science ®Google Scholar
• KuroseSIkedaETokiwaMHikitaNMochizukiMEffects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in ratsExp Eye Res200070171510644416
   PubMed Web of Science ®Google Scholar
• CommodaroAGPeronJPSLopesCTEvaluation of experimental autoimmune uveitis in mice treated with FTY720Invest Ophthalmol Vis Sci20105152568257420019358
   PubMed Web of Science ®Google Scholar
• RaveneyBJCoplandDANicholsonLBDickADFingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory diseaseArch Ophthalmol2008126101390139518852417
   PubMedGoogle Scholar
• ZarbinMAJampolLMJagerRDOphthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosisOphthalmology201312071432143923531349
   PubMed Web of Science ®Google Scholar
• JainNBhattiMTFingolimod-associated macular edema: incidence, detection, and managementNeurology201278967268022371414
   PubMed Web of Science ®Google Scholar
• LinPSuhlerEBRosenbaumJTThe future of uveitis treatmentOphthalmology2014121136537624169255
   PubMed Web of Science ®Google Scholar
• TrittibachPBarkerSEBroderickCALentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitisGene Ther200815221478148818580969
   PubMed Web of Science ®Google Scholar
• TsaiMLHorngCTChenSLXiaoXWangCHTsaoYPSuppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonistMol Vis2009151542155219693263
   PubMed Web of Science ®Google Scholar
• TianLYangPLeiBAAV2-mediated subretinal gene transfer of hIFN-α attenuates experimental autoimmune uveoretinitis in micePLoS One201165e1954221611186
   PubMed Web of Science ®Google Scholar
• ChoiBHwangYKwonHJTumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse modelJ Dermatol Sci2008522879718585901
   PubMed Web of Science ®Google Scholar
• HouYXingLFuSDown-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in ratsGraefes Arch Clin Exp Ophthalmol2009247675576519125271
   PubMed Web of Science ®Google Scholar
• IwataDKitamuraMKitaichiNPrevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNAExp Eye Res2010901414819766630
   PubMed Web of Science ®Google Scholar
• HeYJiaSBZhangWShiJMNew options for uveitis treatmentInt J Ophthalmol20136570270724195053
   PubMed Web of Science ®Google Scholar